Notice
Recent Posts
Recent Comments
Link
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 |
Tags
- 제약바이오
- lilly
- Novo Nordisk
- GPCR
- VK2735
- GLP-1 치료제
- Pegozafermin
- Viking Therapeutics
- 노보노디스크
- il-17 inhibitor
- Semaglutide
- VKTX
- tirzepatide
- GLP-1
- gsbr-1290
- survodutide
- CAR-T
- Pfizer
- danuglipron
- Mash
- 경구용 glp-1
- tern-601
- 자가면역질환 치료제
- glp-1 비만치료제
- 비만치료제
- structure therapeutics
- glp-1 비만
- Nash
- 바이오스터디
- orforglipron
Archives
- Today
- Total
목록2025/04/16 (1)
제약바이오 츄롸이츄롸이
Skye Bioscience (NASDAQ: SKYE) - Nimacimab pre-clinical 데이터
https://ir.skyebioscience.com/news-releases/detail/226/skye-bioscience-demonstrates-over-30-weight-loss-with-nimacimab-and-tirzepatide-combination-in-preclinical-model Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical ModelNimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination wi..
주절주절
2025. 4. 16. 17:00